Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness

Slide: 14 of 34

Triple Therapy Containing Telaprevir Versus Dual Therapy for Patients With HCV Genotype 1 Infection (1 of 2)

Three trials found that the 24-week fixed-duration triple therapy (pegylated interferon alfa [2a or 2b] + ribavirin + telaprevir) was associated with a higher likelihood of achieving a sustained virologic response (SVR) than 48 weeks of dual therapy (pegylated interferon alfa-2a + ribavirin). The pooled relative risk [RR] was 1.5 (95 percent confidence interval [95% CI], 1.3 to 1.8), and the pooled absolute increase in SVR rates was 22 percentage points (95% CI, 13 to 31). The strength of evidence for this finding was rated moderate.

One trial of patients with hepatitis C virus (HCV) genotype 1 infection found that response-guided triple therapy (telaprevir + pegylated interferon alfa-2a + ribavirin) for 8 or 12 weeks and response-guided dual therapy with pegylated interferon alfa-2a and ribavirin for an additional 12 or 36 weeks was associated with a greater likelihood of an SVR than was dual therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks (RR 1.6; 95% CI, 1.4 to 1.9), with an absolute increase in the SVR rate ranging from 25 to 31 percent. The 8-week telaprevir regimen was associated with a slightly lower SVR rate than the 12-week telaprevir regimen (69% vs. 75%). The strength of evidence for this finding was rated low.